Merit Medical announced the successful enrollment of the first patient in its multicenter, prospective, randomized, controlled trial comparing genicular artery embolization, or GAE, using Embosphere Microspheres to corticosteroid injections for the treatment of symptomatic knee osteoarthritis study.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MMSI:
- First Patient Enrolled in Merit Medical’s MOTION Study
- Merit Medical price target raised to $95 from $88 at Piper Sandler
- Merit Medical Announces Projected Preliminary Unaudited Revenue for the Year Ended December 31, 2023 and Plans to Announce Fourth Quarter and Year End 2023 Results and Issue Fiscal Year 2024 Guidance on February 28, 2024
- Merit Medical report FY23 preliminary revenue $1.255B-$1.259B, consensus $1.25B
- Merit Medical upgraded to Buy from Hold at Canaccord
